“Efficacy, Safety, and Tolerability of a Halobetasol 0.01% Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials”. SKIN The Journal of Cutaneous Medicine 3 (November 9, 2019): S28. Accessed April 19, 2025. https://skin.dermsquared.com/skin/article/view/755.